


**PRODUCT: PF-03814735****ALTERNATE NAME:** N-[2-[(1S,4R)-6-[[4-(Cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide**CATALOG #:** B1257-1,5**AMOUNT:** 1 mg, 5 mg**STRUCTURE:****MOLECULAR FORMULA:** C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>**MOLECULAR WEIGHT:** 474.48**CAS NUMBER:** 942487-16-3**APPEARANCE:** White Solid**SOLUBILITY:** DMSO (>40 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light.**DESCRIPTION:** PF-03814735 is an ATP-competitive inhibitor of Aurora kinases A and B with IC<sub>50</sub> values of 0.8 and 0.5 nM respectively. It has shown to block cytokinesis, inhibit cellular proliferation in many tumor cell lines including HCT-116, HL-60 and A549. In vitro experiments have shown that PF 03814735 inhibits the phosphorylation of Aurora B H3 and Aurora A cultured MDA-MB-231 cells.**REFERENCES:** Hook, K.E., et al. (2012). *Mol. Cancer Ther.* **11**, 710-719**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AT-9823 (Cat. No. 2432-5, 25)  
Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)  
AZD1480 (Cat. No. 2315-1, 5)  
CP-690550 (Cat. No. 1622-5, 25)  
Lestaurtinib (Cat. No. 1805-500, 1000)  
MLN8237 (Cat. No. 2718-5,25)  
LLL12 (Cat. No. 1792-5, 25)  
MS-1020 (Cat. No. 1911-1)  
Reversine (Cat. No. 1851-1, 5)  
Ruxolitinib, free base (Cat. No. 2139-5, 25)  
Tozasertib (Cat. No. 1595-25, 100)  
EZSolution™ Tozasertib (Cat. No. 1803-  
TC-S 7010 (Cat. No. B1203-5,25)  
TG101348 (Cat. No. 2314-1, 5)  
Tyrphostin AG 490 (Cat. No. 1570-5)  
WHI-P131 (Cat. No. 1853-5, 25)  
WP1066 (Cat. No. 1809-5, 25)

**USAGE:** *FOR RESEARCH CH USE ONLY! Not to be used in humans*